There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Terns Pharmaceuticals (TERN – Research Report) and OptimizeRx (OPRX – Research Report) with bullish sentiments.
Terns Pharmaceuticals (TERN)
JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Terns Pharmaceuticals today and set a price target of $15.00. The company’s shares closed last Tuesday at $5.99.
According to TipRanks.com, Tuerkcan is a 3-star analyst with an average return of
Terns Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $14.92, which is a 148.7% upside from current levels. In a report issued on April 30, Mizuho Securities also reiterated a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
OptimizeRx (OPRX)
JMP Securities analyst Constantine Davides reiterated a Buy rating on OptimizeRx today and set a price target of $16.00. The company’s shares closed last Tuesday at $10.48.
According to TipRanks.com, Davides is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
OptimizeRx has an analyst consensus of Strong Buy, with a price target consensus of $16.33, a 51.9% upside from current levels. In a report released yesterday, Lake Street also assigned a Buy rating to the stock with a $17.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TERN:
- Terns Pharmaceuticals expects cash to fund operations into 2026
- Terns Pharmaceuticals reports Q1 EPS (30c), consensus (34c)
- Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
- TERN Upcoming Earnings Report: What to Expect?
- Terns Pharmaceuticals appoints Scott Harris as chief development officer
